Parkinson’s Disease / 2015 / Article / Tab 2 / Research Article
Impact of Deep Brain Stimulation on Daily Routine Driving Practice in Patients with Parkinson’s Disease Table 2 The table shows patient characteristics of all drivers and compares patient characteristics of active and inactive drivers at time of DBS surgery (within 3 months before and 12 months after surgery). Furthermore, a comparison of patients who did or did not restart driving is given. Data are shown as means with standard deviation [SD]. Significant different frequencies between active and inactive drivers are labeled with an asterix (
).
Time of DBS surgery Within 3 months preoperatively All (110) Active drivers ( ) Inactive drivers ( ) valueAge (years) 110 61.1 [9.1] 61.2 [8.2] 60.9 [10.3] 0.89 Gender (male) (%) 110 68.2 80.3 50.0 <0.001 H&Y stage (stage) 102 2.8 [0.8] 2.7 [0.8] 3.0 [0.7] 0.06 Disease duration (years) 110 11.9 [5.6] 11.5 [5.4] 12.7 [5.9] 0.29 MMSE (total points) 109 28.5 [1.5] 28.5 [1.6] ( ) 28.5 [1.3] 0.83 MMSE category (%) 109 Normal (>26) 96 88.1 86.2 90.9 0.45 Borderline (24–26) 13 11.9 13.8 9.1 UPDRS III in “ON” (score) 77 18.4 [7.3] 18.0 [6.7] 19.0 [8.1] 0.58 UPDRS III in “OFF” (score) 75 37.7 [11.7] 35.2 [10.3] 41.7 [12.8] 0.02 Improvement in levodopa-test (%) 75 51.8 [17.7] 49.8 [18.0] 54.7 [17.0] 0.23 Within 12 months postoperatively All (110) Active drivers ( ) Inactive drivers ( ) valueAge (years) 110 61.1 [9.1] 60.5 [8.7] 62.3 [9.6] 0.31 Gender (male) (%) 110 67.9 77.9 51.2 0.004 H&Y stage (stage) 102 2.8 [0.8] 2.6 [0.7] 3.1 [0.8] 0.003 MMSE (total points) 108 28.5 [1.5] 28.6 [1.5] ( ) 28.3 [1.5] ( ) 0.37 MMSE category (%) 108 Normal (>26) 95 88.0 91.0 82.9 0.22 Borderline (24–26) 13 12.0 9.0 17.1 Disease duration (years) 110 11.9 [5.6] 11.5 [5.8] 12.8 [5.3] 0.25 UPDRS III in “ON” (score) 77 18.4 [7.3] 17.8 [6.8] 19.2 [8.0] 0.41 UPDRS III in “OFF” (score) 75 37.7 [11.7] 34.7 [10.1] 42.1 [12.7] 0.006 Improvement in levodopa-test (%) 75 51.8 [17.7] 49.4 [19.1] 55.1 [15.4] 0.18 Patients restart driving after DBS surgery All (110) Yes [ ] No [ ] valueAge (years) 110 61.1 [9.1] 56.6 [10.7] 61.5 [8.8] 0.11 Gender (male) (%) 110 68.2 70.0 68.0 0.90 H&Y stage (stage) 102 2.8 [0.8] 2.7 [0.5] 2.8 [0.8] 0.57 MMSE (total points) 109 28.5 [1.5] 28.9 [1.1] ( ) 28.4 [1.5] ( ) 0.36 MMSE category (%) 109 Normal (>26) 96 88.1 100.0 86.9 0.10 Borderline (24–26) 13 11.9 0.0 13.1 Disease duration (years) 110 11.9 [5.6] 12.8 [8.0] 11.9 [5.4] 0.60 UPDRS III in “ON” (score) 77 18.4 [7.3] 18.3 [7.7] 18.4 [7.3] 0.98 UPDRS III in “OFF” (score) 75 37.7 [11.7] 40.7 [9.7] 37.6 [11.9] 0.54 Improvement in levodopa-test (%) 75 51.8 [17.7] 52.5 [20.3] 51.7 [17.6] 0.91